The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights, opens new tab
April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson (JNJ.N), opens new tab and Legend Biotech's (LEGN.O), opens new tab Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.
